Lupin launches Droxidopa capsules

The product is manufactured at Lupin’s facility in Nagpur, India, according to a statement released by the company.

92
Medicine Capsule
Picture: Pixabay

Lupin yesterday launched Droxidopa capsules, 100 mg, 200 mg and 300 mg, having received an approval from the United States Food and Drug Administration (USFDA).

The product is manufactured at Lupin’s facility in Nagpur, India, according to a statement released by the company.

Droxidopa Capsules, 100 mg, 200 mg and 300 mg is a generic equivalent of Northera capsules, 100 mg, 200 mg and 300 mg, of Lundbeck NA.

It is indicated for the treatment of orthostatic dizziness, light headedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

Droxidopa Capsules had estimated annual sales of $294 million in the US, according to IQVIA, added the statement.

Sun Pharma launches a novel formulation for Cough management

Lincoln Pharma plans to launch Cephalosporin products

Natural Antioxidant Gamma Oryzanol launched in India

Dr. Reddy’s Labs launches Rx drug Minoxidil for treatment of hair

Dr Reddy’s launches Reddy-Lenalidomide

Lupin launches drug for Asthma patient

DCGI allows Serum Institute for Vaccine trial on kids aged…

Telangana sees huge expansion in Drug Manufacturing

Sun Pharma launches a novel formulation for Cough management

Pfizer to soon submit data on C-19 vaccine for kids aged…

Practical training to Pharmacy Students in industrial units

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner